ACT and 500 Startups Istanbul invest in Spirohome, a cutting-edge digital health platform for tracking and managing the conditions of asthma, COPD & CF patients.
ACT and 500 Istanbul have led the seed funding round to Spirohome, an eHealth platform solution designed for asthma, Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF) patients along with health enthusiasts who want to be aware of their lung condition.
Spirohome’s solution includes a personal smart spirometer, an integrated mobile app and a web platform for both patients and health professionals. Spirohome enables patients to monitor their situation and prevent attacks while avoiding unnecessary hospital visits. Patent pending technology behind the personal spirometer uses ultrasonic flow sensing which is the most advanced technology for spirometer devices available in the market. Spirohome captures lung function with medical-grade accuracy without requiring maintenance or calibration for personal use.
Pulmonary chronic lung diseases such as asthma, COPD and CF are characterized by recurrent attacks of breathlessness and wheezing, which vary in severity and frequency from person to person. Many patients are unaware of, or simply ignore their condition, silently accepting an inability to improve their health . Nevertheless, their lung values deteriorate significantly even before the symptoms occur, hindering their awareness of their pathology. Therefore, when the crisis hits, it usually ends with uncontrolled treatment or unwanted emergency room visits.
Establiashed in Metutech, Spirohome will use the proceeds of the funding round to further develop the platform, grow the Spirohome team and apply for both the CE mark, and the FDA regulatory process.
For more information: